Dr. Agarwals Health Care Ltd

Dr. Agarwals Health Care Limited announced that its direct wholly owned subsidiary, Orbit Healthcare Services (Mauritius) Limited, has confirmed that Orbit Healthcare Services Nigeria Ltd. has become its wholly owned subsidiary. Consequently, Orbit Healthcare Services Nigeria Ltd. is now an indirect/step-down wholly owned subsidiary of Dr. Agarwals Health Care Limited. This update follows an earlier communication dated August 04, 2026, regarding the proposed subsidiary in Nigeria.

Dr. Agarwals Health Care Ltd has submitted its Annual Report for the Financial Year 2025-26. The company has scheduled its Sixteenth Annual General Meeting (AGM) for September 21, 2026, to be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM). The Annual Report and AGM Notice have been made available on the company's website. NSDL has been engaged for hosting the AGM and facilitating e-voting. The remote e-voting period will commence on September 17, 2026, and conclude on September 20, 2026. The cut-off date for e-voting eligibility is August 21, 2026.

Dr. Agarwals Health Care Ltd has announced the convening of its Sixteenth Annual General Meeting (AGM) scheduled for September 21, 2026. The AGM will be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), with NSDL facilitating the process and e-voting. The Annual Report for the financial year 2025-26, along with the AGM notice, has been submitted and made available on the company's website. The cut-off date for e-voting eligibility is August 21, 2026, with remote e-voting commencing on September 17, 2026, and concluding on September 20, 2026. Members are advised to refer to the AGM notice for detailed instructions on voting and meeting attendance.

Dr. Agarwal's Eye Hospital Limited, a subsidiary of Dr. Agarwals Health Care Ltd, has launched the World's First Pinhole Pupilloplasty (PPP) Centre at its Chennai facility. Inaugurated on August 27, 2026, by the Chief Minister of Tamil Nadu, the centre will offer advanced treatments for complex corneal disorders using the pioneering PPP technique developed by Dr. Amar Agarwal. This procedure improves vision by modifying the eye's optical system without requiring donor corneal tissue, addressing a significant global shortage. The centre aims to enhance access to this innovation, provide structured patient pathways, and serve as a training platform for ophthalmologists.

Catalyst Trusteeship Limited, acting as a pledgee for lenders to Hyperion Investments Pte. Ltd., has created a new pledge over 7,538,303 equity shares of Dr. Agarwals Health Care Limited. These shares represent 2.38% of the company's total share capital. This new pledge was created on August 21, 2026, and forms part of shares previously released from an earlier pledge. The total encumbered shares held by Catalyst Trusteeship now stand at 49,033,988, representing 15.47% of the total share capital.

DB International Trust (Singapore) Ltd, acting as offshore security agent for lenders to Hyperion Investments Pte. Ltd., has filed a disclosure under SEBI's Takeover Regulations. This filing pertains to a change in shareholding of Dr. Agarwals Health Care Limited, where the borrower (Hyperion Investments Pte. Ltd.) has disposed of 24,160,000 equity shares. This disposal follows a partial release of pledge by the onshore security agent. Prior to this transaction, the borrower held approximately 23.09% of the target company's shares, which were encumbered.

Claymore Investments (Mauritius) Pte Ltd has disclosed the sale of 1,59,00,000 equity shares, representing 5.02% of the total share capital, in Dr. Agarwals Health Care Limited. The sale was conducted on the open market. Following the transaction, Claymore Investments' holding has reduced to 5.17% (or 5.14% on a diluted basis) of the total share capital. Arvon Investments Pte. Ltd., identified as a Person Acting in Concert (PAC), holds 9.87% (or 9.80% diluted) of the company's shares. The total diluted share capital of the company post-sale is approximately INR 31.93 crore.

Hyperion Investments Pte Ltd has disclosed the sale of 24,160,000 equity shares, representing 7.62% of the total share capital, in Dr. Agarwals Health Care Limited. This transaction reduces Hyperion's holding from 23.09% to 15.47%. The sale was conducted through stock exchanges. The total equity share capital of the company remains unchanged at 316,983,028 shares.

Invesco Mutual Fund, through various schemes, has increased its aggregate holding in Dr. Agarwals Health Care Limited to 5.2125% of the paid-up share capital. This disclosure under SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, details the acquisition of 69,38,186 equity shares, bringing the total holding to 1,65,25,136 shares as of August 12, 2026. The acquisition was made via the open market. The total diluted share capital of the company remains unchanged.

Catalyst Trusteeship Limited, acting as a pledgee for lenders to Hyperion Investments Pte. Ltd., has filed a disclosure under SEBI's Takeover Code regarding the release of encumbrance on 31,698,303 equity shares of Dr. Agarwals Health Care Limited. This represents approximately 10.00% of the total share capital. The initial pledge involved 73,193,988 shares (23.09%) as security for a USD 100,000,000 facility. Following this partial release, Catalyst Trusteeship now holds encumbrance over 41,495,685 shares (13.09%). The total equity share capital of the company remains unchanged at 316,983,028 shares.